Compare LEU & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEU | IRTC |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 5.8B |
| IPO Year | 1998 | 2016 |
| Metric | LEU | IRTC |
|---|---|---|
| Price | $233.33 | $171.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $235.80 | $203.93 |
| AVG Volume (30 Days) | ★ 926.0K | 479.0K |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | N/A |
| EPS | ★ 6.17 | N/A |
| Revenue | $454,100,000.00 | ★ $702,573,000.00 |
| Revenue This Year | $1.93 | $27.20 |
| Revenue Next Year | $7.86 | $16.89 |
| P/E Ratio | $40.36 | ★ N/A |
| Revenue Growth | 15.25 | ★ 25.45 |
| 52 Week Low | $49.40 | $84.17 |
| 52 Week High | $464.25 | $212.00 |
| Indicator | LEU | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 35.61 | 41.81 |
| Support Level | $248.93 | $167.07 |
| Resistance Level | $274.00 | $187.98 |
| Average True Range (ATR) | 17.51 | 6.26 |
| MACD | 0.89 | -1.30 |
| Stochastic Oscillator | 0.69 | 16.65 |
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.